Tiapride. A review of its pharmacology and therapeutic potential in the management of alcohol dependence syndrome.
Tiapride, an atypical neuroleptic agent, is a selective dopamine D2-receptor antagonist with little propensity for causing catalepsy and sedation. It shows preferential activity at receptors previously sensitised to dopamine and those located extrastriatally. Tiapride demonstrates antidyskinetic activity reflecting antidopaminergic actions, and also anxiolytic activity mediated by mechanisms that are poorly understood. Unlike the benzodiazepines, tiapride does not affect vigilance and has a low potential for interaction with alcohol (ethanol), and possibly for abuse. Tiapride facilitates management of alcohol withdrawal, but its use in patients at risk of severe reactions in acute withdrawal should be accompanied by adjunct therapy for hallucinosis and seizures. Since it may prove difficult to identify such patients and there is also a small risk of neuroleptic malignant syndrome (particularly with parenteral administration), the usefulness of tiapride in this setting is likely to be limited. Nevertheless, relative freedom from the complications associated with benzodiazepine therapy suggest a possible role for the drug in the treatment of individuals suitable for alcohol detoxification as outpatients. Preliminary clinical studies in alcoholic patients following detoxification have shown that tiapride ameliorates psychological distress, improves abstinence, and reduces drinking behaviour, and in the short term facilitates reintegration within society. These benefits were associated with reduced consumption of health care resources. However, the potential risk of tardive dyskinesia at the dosage employed (300 mg/day) requires evaluation and necessitates medical supervision. Thus, with its lack of adverse effects on vigilance and low propensity for interaction with alcohol and possibly for abuse, tiapride will probably find particular use in the management of alcoholic patients suitable for detoxification in an outpatient setting; and, if initial findings are confirmed in large well-designed trials, in the short term (< or = 6 months) therapy of reformed alcoholic patients under medical supervision.
Peters
D H
DH
Adis International Limited, Auckland, New Zealand.
Faulds
D
D
D000284:Administration, Oral; D000430:Alcohol Withdrawal Delirium / Q000517:prevention & control; D000818:Animals; D001682:Biological Availability; D000431:Ethanol / Q000009:adverse effects*; D006207:Half-Life; D006801:Humans; D007273:Injections, Intramuscular; D016032:Randomized Controlled Trials as Topic; D011954:Receptors, Dopamine / Q000187:drug effects; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy* / Q000503:physiopathology / Q000534:rehabilitation; D013976:Tiapamil Hydrochloride / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*
D011954:Receptors, Dopamine; D000431:Ethanol; D013976:Tiapamil Hydrochloride